J&J: TREATMENT WITH NIPOCALIMAB PLUS SOC MET STUDY'S PRIMARY ENDPOINT OF REDUCTION IN TOTAL SERUM IGG (-69%)

Reuters · 10/15 12:00

Please log in to view news